Recommendations for the prevention, mitigation and containment of the emerging SARS-CoV-2 (COVID-19) pandemic in haemodialysis centres.
COVID-19
coronavirus
end-stage kidney disease
haemodialysis
pandemic
Journal
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402
Informations de publication
Date de publication:
01 05 2020
01 05 2020
Historique:
received:
14
03
2020
accepted:
14
03
2020
pubmed:
21
3
2020
medline:
13
5
2020
entrez:
21
3
2020
Statut:
ppublish
Résumé
COVID-19, a disease caused by a novel coronavirus, is a major global human threat that has turned into a pandemic. This novel coronavirus has specifically high morbidity in the elderly and in comorbid populations. Uraemic patients on dialysis combine an intrinsic fragility and a very frequent burden of comorbidities with a specific setting in which many patients are repeatedly treated in the same area (haemodialysis centres). Moreover, if infected, the intensity of dialysis requiring specialized resources and staff is further complicated by requirements for isolation, control and prevention, putting healthcare systems under exceptional additional strain. Therefore, all measures to slow if not to eradicate the pandemic and to control unmanageably high incidence rates must be taken very seriously. The aim of the present review of the European Dialysis (EUDIAL) Working Group of ERA-EDTA is to provide recommendations for the prevention, mitigation and containment in haemodialysis centres of the emerging COVID-19 pandemic. The management of patients on dialysis affected by COVID-19 must be carried out according to strict protocols to minimize the risk for other patients and personnel taking care of these patients. Measures of prevention, protection, screening, isolation and distribution have been shown to be efficient in similar settings. They are essential in the management of the pandemic and should be taken in the early stages of the disease.
Identifiants
pubmed: 32196116
pii: 5810637
doi: 10.1093/ndt/gfaa069
pmc: PMC7184437
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
737-741Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
Références
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Medicine (Baltimore). 2020 Jan;99(3):e18782
pubmed: 32011472
Kidney Int. 2020 May;97(5):824-828
pubmed: 32204907
BMJ. 2020 Feb 18;368:m641
pubmed: 32071063
Ann Intern Med. 2020 May 5;172(9):577-582
pubmed: 32150748
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Adv Chronic Kidney Dis. 2019 Jan;26(1):8-15
pubmed: 30876622
Nat Rev Nephrol. 2013 May;9(5):255-65
pubmed: 23507826